Deep Intelligence Across Industries

Company Headquarter: Wayne, Pennsylvania, US Founded: 1981 Workforce: 14,000+ Employees (2017) Company Working: Teleflex Incorporated is engaged in designing, developing, manufacturing, and supplying single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications globally. Its vascular access product portfolio comprises arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, and devices for treating coronary and peripheral vascular disease. Moreover, the company serves hospitals and healthcare providers, medical device manufacturers, and home care markets.

Company Headquarter: ‎ California, US Founded: 1989 Workforce: ~200 Company Working: Sorrento Therapeutics (Sorrento) is an antibody-centric, clinical stage biopharmaceutical company that develops new treatments for cancer, inflammation, and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar antibodies, as well as clinical CAR-T therapies targeting solid tumors. It has a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB), clinical stage CAR-T, intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADC), and an oncolytic virus (Sephrehvir).

Company Headquarters: UK, Europe Founded: 2014 Company Working: Autolus Therapeutics PLC (Autolus), a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company functions as a single operating segment, which is the business of developing and commercializing gene therapies.

Company Headquarters: California, US Founded: 2009 Company Working: Kite Pharma, a clinical-stage biopharmaceutical company that is focused on the development and commercialization of novel cancer immunotherapy products. The company has been developing a pipeline of engineered, autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a CAR-based therapy is in Phase II of clinical trials. KTE-C19 is likely to aid in the treatment of patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. The company has one operating segment, which primarily focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company operates as a cell therapy subsidiary of Gilead Sciences, Inc.

Company Headquarter: US Founded: 1892 Workforce: 283,000 Company Working: General Electric Company is a technology and financial services company that develops and manufactures products for the generation, transmission, distribution, control, and utilization of electricity. The company offers aircraft engines, power generation, water processing, security technology, medical imaging, business and consumer financing, media content, and industrial products. GE operates through two major segments—industrial and capital. The industrial segment consists of 8 different sub-segments, namely, power, oil & gas, energy, aviation, healthcare, transportation, appliances and lighting, and GE capital. The Power segment offers power generation and energy production. The Oil & Gas segment provides mission-critical equipment for Oil & Gas companies. The Energy segment provides wind turbine platforms, hydropower products and services, and blades for wind turbines. The Aviation segment manufactures jet engines, turboprops, maintenance, engineering, and overhaul services. The Healthcare segment provides diagnostic imaging and clinical systems, drug discovery solutions, gene therapy technologies, and medical technologies. The Transportation segment offers freight and passenger locomotives, rail parts, data analytics, and rail integrated software solutions. The Appliances & Lighting segment manufactures LED products, refrigerators, cooktops, microwave ovens, hybrid water heaters, energy efficiency, and productivity solutions. The GE Capital segment offers financial services such as commercial loans and leases, consulting services, and fleet management. GE Power’s Grid Solutions is one of the subsidiaries which provide the energy leader that provides technology, solutions, and services across the entire energy value chain. The company operates across the world in the Americas, EMEA (Europe, Middle East, and Africa), and Asia-Pacific and has several subsidiaries including GE Capital, GE Digital, GE Energy Connections, and GE Global Research.

Company Headquarter: Milan, Italy Founded: 1994 Workforce: 3,450+ Company Working: Bracco Diagnostic Inc. (Bracco) is an international healthcare company, majorly focused on diagnostic imaging products. It has a wide portfolio consisting of over 1,800 patents. Its main products include contrast agents and medical substances used to improve the diagnostic accuracy of biomedical imaging. Its products are sold in over 100 countries, both directly and indirectly through branches, joint ventures, license, and distribution agreements. The company holds a leading position in important geographical areas such as Japan, North America, and Europe. Bracco’s production activities are carried out in Italy, Canada, Switzerland, Germany, Japan, and China.

Company Headquarters: Texas, US Founded: 2016 Company Working: Nuvectra Corporation offers its devices for neurological indications such as spinal cord stimulation. Moreover, the company is continuously engaged in improving and developing medical devices for neurological conditions, such as sacral nerve stimulation and deep brain stimulation.

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin;} Company Headquarters Walldorf, Germany Founded: 1972 Workforce: ~96,498 Company Working: SAP SE (SAP) is a leading provider of enterprise applications and software solutions. The company offers software-related services and enterprise application software globally. SAP SE operates through the applications, technology & services, and SAP business network business segments. The applications, technology & services segment generates its revenue primarily by selling software licenses and subscriptions to cloud applications and related services, as well as by implementing software products and education services. The SAP business network segment has basically emerged from combining all SAP network offerings into one network, which entirely covers temporary workforce sourcing, other procurement, end-to-end travel, and business travel expense management. Apart from Germany, the company operates through offices located in the Americas, Asia-Pacific, the Middle East & Africa and, Europe. SAP SE has several subsidiaries, including Hybris, Success Factors, Fieldglass, and SAP Ariba, situated at various locations globally. The company has approximately 15,000 partners globally.

Company Headquarters: Bromma, Sweden Founded: 2006 Company Working: Moberg Pharma AB develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company comprises only one area of operation, which is the development and commercialization of medical products. MOB-015 is the next generation of nail fungus treatment and BUPI is a new pain treatment for mouth and throat for cancer patients with oral mucositis. MOB-015 is currently undergoing two parallel phase 3 studies with expected topline results towards the end of 2019 and the second quarter of 2020, respectively. It has also signed two license agreements with leading players in Europe and Canada. It markets its products directly in the US, as well as through a network of distributors in approximately 40 countries.